STOCK TITAN

Evaxion Biotech A/S American Depositary Share - EVAX STOCK NEWS

Welcome to our dedicated page for Evaxion Biotech A/S American Depositary Share news (Ticker: EVAX), a resource for investors and traders seeking the latest updates and insights on Evaxion Biotech A/S American Depositary Share stock.

Evaxion Biotech A/S (symbol: EVAX) is a clinical-stage biotechnology company founded in 2008 with the mission to address some of the most significant global health challenges using artificial intelligence (AI). The company has developed robust platforms for creating novel vaccines and therapies. Evaxion's primary AI platforms, PIONEER and EDEN, utilize advanced in silico tools including big data, AI, and supercomputing to predict, rank, and optimize epitopes and antigens that stimulate highly protective immune responses against cancers and infectious diseases.

Evaxion's EDEN platform focuses on the rapid discovery of new antigens eliciting cross-protective immune responses against bacterial pathogens. On the other hand, the PIONEER platform identifies epitopes of mutated proteins to activate the body's natural immune responses. Additionally, the company has developed two more AI platforms, RAVEN and ObsERV, to further enhance its drug development pipeline.

The company's leading product candidates include EVX-01 and EVX-02, which are under development for cancer treatment, as well as EVX-03, a pre-clinical candidate for non-small-cell lung cancer (NSCLC). With a strong focus on AI-driven drug discovery and development, Evaxion aims to create innovative immunotherapies with improved efficacy for patients with unmet medical needs.

Recent news highlights key company activities, such as:

  • A replay of the R&D Day presentations is available on the company's website.
  • Information about the EVX-01 Phase 2 clinical trial.
  • The company resolved a Nasdaq equity deficiency issue stemming from the IFRS accounting treatment of investor warrants.

To learn more about Evaxion Biotech A/S and its innovative AI-driven approaches, please visit Evaxion Biotech.

Rhea-AI Summary
Evaxion Biotech A/S (NASDAQ: EVAX) announces a private placement financing to raise gross proceeds of approximately $5.3 million, with MSD Global Health Innovation Fund (MSD GHI) contributing 25% of the total offering amount. The Private Placement includes participation from existing and new shareholders, with significant involvement from the Company’s management and board of directors. The Private Placement involves the issuance and sale of 9,726,898 of the Company’s ordinary shares and accompanying warrants at a purchase price of $0.544 per Ordinary Share for an aggregate purchase price of $5.3 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.96%
Tags
none
-
Rhea-AI Summary
Evaxion Biotech (EVAX) presents breakthrough achievement in precision cancer vaccines at the 65th ASH Annual Meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.22%
Tags
AI
-
Rhea-AI Summary
Evaxion Biotech A/S (NASDAQ: EVAX) presents a novel AI model at the Biomarkers & Precision Oncology Europe conference in Berlin, Germany, designed to predict patient responses to cancer immunotherapy. The model aims to improve patient outcomes, reduce healthcare costs, and is scalable for broader applications. Evaxion plans to pursue a partnership-based approach towards a commercial offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.34%
Tags
AI
Rhea-AI Summary
Evaxion Biotech A/S (NASDAQ: EVAX) is hosting an online webinar on November 8th featuring Professor Adnan Khattak, the principal investigator of the EVX-01 clinical trial. EVX-01 is Evaxion's lead clinical asset based on its AI-Immunology™ platform. The webinar will discuss the promising results of the Phase 1 trial and provide an update on the Phase 2 trial, which appears to confirm the benefits of this innovative immunotherapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.63%
Tags
-
Rhea-AI Summary
Evaxion Biotech announces positive initial results from the EVX-01 Phase 2 clinical trial, confirming previous successful Phase 1 findings. The trial showed a significant and continuous tumor reduction in a metastatic melanoma patient with initial progressive disease. The company's AI-Immunology™ platform demonstrated the ability to identify therapeutically relevant cancer vaccine targets. A comprehensive clinical update will be presented at the Society for Immunotherapy of Cancer (SITC) 38th annual meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.79%
Tags
-
Rhea-AI Summary
Evaxion Biotech will present clinical readouts on its two personalized cancer vaccine trials at the annual meeting of the Society for Immunotherapy of Cancer. The results will be presented in two posters, showcasing the positive clinical evidence for the company's AI-immunology platform.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.59%
Tags
Rhea-AI Summary
Evaxion Biotech receives notification letter from Nasdaq regarding bid price deficiency
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Evaxion Biotech announces collaboration with Afrigen Biologics for the development of a gonorrhea vaccine based on Evaxion's EDEN™ platform
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
41.67%
Tags
partnership
-
Rhea-AI Summary
Evaxion announces collaboration for AI-designed vaccine candidate against undisclosed bacterial pathogen
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-20.48%
Tags
none
Rhea-AI Summary
Evaxion achieves groundbreaking milestone in vaccine discovery with AI-powered platform EDENTM
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.52%
Tags
AI

FAQ

What is the current stock price of Evaxion Biotech A/S American Depositary Share (EVAX)?

The current stock price of Evaxion Biotech A/S American Depositary Share (EVAX) is $0.92 as of December 20, 2024.

What is the market cap of Evaxion Biotech A/S American Depositary Share (EVAX)?

The market cap of Evaxion Biotech A/S American Depositary Share (EVAX) is approximately 5.3M.

What does Evaxion Biotech A/S specialize in?

Evaxion Biotech A/S specializes in developing novel vaccines and therapies using artificial intelligence to solve significant health challenges.

What are the main AI platforms used by Evaxion Biotech?

Evaxion Biotech uses the PIONEER, EDEN, RAVEN, and ObsERV AI platforms for drug discovery and development.

What are Evaxion's leading product candidates?

Evaxion's leading product candidates include EVX-01 and EVX-02 for cancer treatment and EVX-03 for non-small-cell lung cancer.

What recent developments have taken place at Evaxion Biotech?

Recent developments include a replay of the R&D Day presentations, information about the EVX-01 Phase 2 clinical trial, and a resolution of a Nasdaq equity deficiency issue.

When was Evaxion Biotech A/S founded?

Evaxion Biotech A/S was founded in 2008.

How does the EDEN platform contribute to Evaxion's research?

The EDEN platform aids in the rapid discovery of novel antigens that elicit cross-protective immune responses against bacterial pathogens.

What is PIONEER platform's role in Evaxion's operations?

The PIONEER platform identifies epitopes of mutated proteins to activate the body's natural immune responses, particularly in cancer treatments.

What kind of financial challenges has Evaxion recently addressed?

Evaxion addressed a Nasdaq equity deficiency issue related to the IFRS accounting treatment of investor warrants by converting the exercise price from USD to DKK.

Where can I find more information about Evaxion's recent activities?

More information about Evaxion's recent activities can be found on their official website at www.evaxion-biotech.ai.

What is the mission of Evaxion Biotech A/S?

The mission of Evaxion Biotech A/S is to tackle significant global health challenges using artificial intelligence to develop novel vaccines and immunotherapies.

Evaxion Biotech A/S American Depositary Share

Nasdaq:EVAX

EVAX Rankings

EVAX Stock Data

5.34M
4.17M
25.25%
9.9%
0.61%
Biotechnology
Healthcare
Link
United States of America
Horsholm